早期妊娠HbA1c作为妊娠期糖尿病初筛试验:三项前瞻性队列研究结果
在印度和肯尼亚两个中低收入国家及英国多族裔人群中开展前瞻性队列研究,评估早期妊娠HbA1c单独或联合年龄、BMI、糖尿病家族史组成的复合风险评分预测24-28周妊娠期糖尿病的效能。结果显示早期妊娠HbA1c与妊娠期糖尿病独立相关,采用人群特异性双阈值筛查策略可减少50-64%的口服葡萄糖耐量试验需求。
要点
- 早期妊娠HbA1c与24-28周妊娠期糖尿病独立相关,调整后风险比在印度为1.60,肯尼亚为3.49,英国为4.72。
- 复合风险评分模型(HbA1c联合年龄、BMI、糖尿病家族史)对妊娠期糖尿病阳性预测效能最佳。
- 人群特异性双阈值筛查策略可减少50-64%的口服葡萄糖耐量试验需求。
核心结论
- 早期妊娠HbA1c为妊娠期糖尿病提供了一种简单的筛查试验,使最高风险者可早期干预并大幅减少口服葡萄糖耐量试验需求,在中低收入国家亦可采用即时检测HbA1c完成。
研究设计与样本
- STRiDE为前瞻性队列研究,在印度南部7个中心和肯尼亚西部7个中心开展,纳入年龄18-50岁、经超声确定孕周小于16周(肯尼亚小于20周)的孕妇。
- 研究评估早期妊娠HbA1c(静脉血和毛细血管即时检测)单独或联合年龄、BMI、糖尿病家族史组成的复合风险评分对24-28周妊娠期糖尿病的预测效能。
- 研究纳入印度3070名参与者和肯尼亚4104名参与者,另从PRiDE队列纳入4320名参与者。
- 妊娠期糖尿病采用现行WHO标准诊断。
主要发现
- 24-28周口服葡萄糖耐量试验诊断的妊娠期糖尿病患病率在印度为19.2%,肯尼亚为3.0%,英国为14.5%。
- 早期妊娠HbA1c与24-28周妊娠期糖尿病发病独立相关,调整后风险比在印度为1.60(95% CI 1.19-2.16),肯尼亚为3.49(95% CI 2.8-4.34),英国为4.72(95% CI 3.82-5.82)。
- 联合静脉血或即时检测HbA1c与年龄、BMI、糖尿病家族史的复合风险评分模型对妊娠期糖尿病检测阳性的预测效能最佳。
- 采用早期妊娠复合风险评分进行人群特异性双阈值纳入和排除妊娠期糖尿病的筛查策略,可减少50-64%的口服葡萄糖耐量试验需求。
- HbA1c单独模型的阈值:印度纳入阈值为5.4%、排除阈值为4.9%;肯尼亚纳入阈值为6.0%、排除阈值为5.2%;英国纳入阈值为5.6%、排除阈值为5.2%。
关键数值与推荐
- 早期妊娠HbA1c单独模型的纳入阈值:印度5.4%,肯尼亚6.0%,英国5.6%。
- 早期妊娠HbA1c单独模型的排除阈值:印度4.9%,肯尼亚5.2%,英国5.2%。
临床怎么用
- 早期妊娠HbA1c可作为妊娠期糖尿病的简单筛查试验,使最高风险者接受早期干预。
- 采用人群特异性双阈值筛查策略可大幅减少口服葡萄糖耐量试验需求。
- 在中低收入国家可采用即时检测HbA1c完成筛查。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than 90% of gestational diabetes cases are estimated to occur in low-income and middle-income countries (LMICs). Most current guidelines recommend an oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The OGTT is burdensome, especially in LMICs, resulting in a high proportion of women not being screened. We aimed to develop a simple and effective screening strategy for gestational diabetes. METHODS: STRiDE, a prospective cohort study, was set up in seven centres in south India and seven centres in western Kenya, and included pregnant women aged 18-50 years of age and at less than 16 weeks of gestation (<20 weeks in Kenya), confirmed by dating ultrasound. We assessed the efficacy of early pregnancy HbA1c (venous and capillary point-of-care), either alone or as part of a composite risk score with age, BMI, and family history of diabetes, in predicting gestational diabetes at 24-28 weeks of gestation, in two LMICs (India and Kenya) and in a UK multi-ethnic population from the PRiDE study. A key secondary outcome was to assess whether an early pregnancy composite risk score can reduce the need for OGTTs. Gestational diabetes was diagnosed using current WHO criteria. FINDINGS: Between Feb 15, 2016, Dec 13, 2019, we enrolled 3070 participants in India and 4104 in Kenya. 4320 participants were included from the PRiDE cohort. Gestational diabetes prevalence by OGTT at 24-28 weeks was 19·2% in India, 3·0% in Kenya, and 14·5% in the UK. Early pregnancy HbA1c was independently associated with incidence of gestational diabetes at 24-28 weeks of gestation. Adjusted risk ratios were 1·60 (95% CI 1·19-2·16) in India, 3·49 (2·8-4·34) in Kenya, and 4·72 (3·82-5·82) in the UK. Composite risk score models that combined venous or point-of-care HbA1c with age, BMI, and family history of diabetes best predicted testing positive for gestational diabetes. A population-specific, two-threshold screening strategy of rule-in and rule-out gestational diabetes using early pregnancy composite risk score could reduce the requirement of OGTTs by 50-64%. For the HbA1c-alone model, the thresholds were 5·4% (rule in) and 4·9% (rule out) in India, 6·0% (rule in) and 5·2% (rule out) in Kenya, and 5·6% (rule in) and 5·2% (rule out) in the UK. INTERPRETATION: Early pregnancy HbA1c offers a simple screening test for gestational diabetes, allowing those at highest risk to receive early intervention and greatly reduce the need for OGTTs. This can also be carried out using point-of-care HbA1c in LMICs. FUNDING: UK Medical Research Council and the Indian Department of Biotechnology.
引用
- Saravanan P, Deepa M, Ahmed Z, et al. Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts. Lancet Diabetes Endocrinol. 2024. PMID: 38936371. doi:10.1016/S2213-8587(24)00151-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。